Chronic subclinical inflammation is a key driver of fibrogenesis in MASLD, mediated by an interplay of cytokines such as IL-6, TNF-α, and IL-1β, which promote hepatocellular injury, immune activation, and hepatic stellate cell (HSC) stimulation [1,7,14]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.